NIAID announces $3.05 million funding opportunity for AIDS research

The National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, recently announced a funding opportunity for research related to developing an effective vaccine for the human immunodeficiency virus.

The funding opportunity announcement seeks institutions and organizations to propose innovative, high-impact, high-risk research to identify novel vaccine targets and concepts that will enable the development and design of an effective immunogen that could lead to long-term prevention from HIV acquisition. The NIAID will commit an estimated $3.05 million in total costs to fund five to 10 applications that are submitted in response to the FOA. The FOA was posted on Tuesday with the application due by July 24.

The FOA emphasizes early discovery research incorporating new ideas that could lead to developing new conventional or outside-the-box approaches for vaccines that could have significant impact on the design of novel immunogens or immunization strategies for an effective vaccine for HIV.

The program does not require research expertise in HIV prevention as a prerequisite and is open to both established and new investigators.

Applicants must state clearly how the new proposed idea, approach or rationale offers a potential solution for preventing the acquisition of infection, could be tested stringently and potentially implemented, differ from current or previously unsuccessful approaches, and will inform, contribute or provide more than incremental knowledge to the field regardless of the proposed work's outcome.

Application budgets will be limited to $350,000 per year in direct costs over a four-year period with an additional $150,000 in direct costs in any year when non-human primate research is proposed and justified.

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!